These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22926034)

  • 41. Lipid-altering therapies and the progression of atherosclerotic disease.
    Wierzbicki AS
    Cardiovasc Intervent Radiol; 2007; 30(2):155-60. PubMed ID: 17206389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.
    Shah PK
    Eur Heart J; 2007 Jan; 28(1):5-12. PubMed ID: 17121756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
    Albert MA; Staggers J; Chew P; Ridker PM;
    Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature.
    Diamantis E; Kyriakos G; Quiles-Sanchez LV; Farmaki P; Troupis T
    Curr Cardiol Rev; 2017; 13(3):209-216. PubMed ID: 28462692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Platelet activation, inflammatory mediators and hypercholesterolemia.
    Ferroni P; Basili S; Davi G
    Curr Vasc Pharmacol; 2003 Jun; 1(2):157-69. PubMed ID: 15320841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel anti-inflammatory therapies for the treatment of atherosclerosis.
    Khan R; Spagnoli V; Tardif JC; L'Allier PL
    Atherosclerosis; 2015 Jun; 240(2):497-509. PubMed ID: 25917947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel anti-inflammatory strategies in atherosclerosis.
    van der Valk FM; van Wijk DF; Stroes ES
    Curr Opin Lipidol; 2012 Dec; 23(6):532-9. PubMed ID: 23160400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TLR4 signaling: a potential therapeutic target in ischemic coronary artery disease.
    Jia SJ; Niu PP; Cong JZ; Zhang BK; Zhao M
    Int Immunopharmacol; 2014 Nov; 23(1):54-9. PubMed ID: 25158302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Role of Colchicine in Acute Coronary Syndromes.
    Vaidya K; Martínez G; Patel S
    Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation.
    Aukrust P; Yndestad A; Smith C; Sandberg WJ; Ueland T; Waehre T; Halvorsen B; Gullestad L; Damås JK
    Expert Opin Pharmacother; 2005 Oct; 6(13):2169-80. PubMed ID: 16218879
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of Allergic Inflammatory Cells in Coronary Artery Disease.
    Niccoli G; Montone RA; Sabato V; Crea F
    Circulation; 2018 Oct; 138(16):1736-1748. PubMed ID: 30354461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regression of atherosclerosis.
    Arsenault BJ; Kritikou EA; Tardif JC
    Curr Cardiol Rep; 2012 Aug; 14(4):443-9. PubMed ID: 22706914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
    Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Markers of inflammation and their clinical significance.
    Ballantyne CM; Nambi V
    Atheroscler Suppl; 2005 May; 6(2):21-9. PubMed ID: 15823493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging anti-inflammatory drugs for atherosclerosis.
    Berman JP; Farkouh ME; Rosenson RS
    Expert Opin Emerg Drugs; 2013 Jun; 18(2):193-205. PubMed ID: 23675745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention.
    Bhatt DL
    Am J Cardiol; 2008 May; 101(10A):4D-13D. PubMed ID: 18474273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic Role of Innovative Anti-Inflammatory Medications in the Prevention of Acute Coronary Syndrome.
    Pashun RA; Frishman WH
    Cardiol Rev; 2015; 23(5):252-60. PubMed ID: 25741604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches.
    Tsioufis P; Theofilis P; Tsioufis K; Tousoulis D
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ali M; Girgis S; Hassan A; Rudick S; Becker RC
    Coron Artery Dis; 2018 Aug; 29(5):429-437. PubMed ID: 29652673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.